1. Veklury® *(remdesivir)*

Q1–Q3 2020 sales: $873 million

Sponsor(s): Gilead Sciences

Type: SARS-CoV-2 nucleotide analog RNA polymerase inhibitor

Indication(s): Adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization

FDA Approval Date: October 22, 2020

2. Tepezza® *(teprotumumab-trbw)*

Q1–Q3 2020 sales: $476.3 million

Sponsor(s): Horizon Therapeutics

Type: Insulin-like growth factor-1 receptor inhibitor

Indication(s): Thyroid eye disease

FDA Approval Date: January 21, 2020

3. Reblozyl® *(luspatercept-aamt)*

Q1–Q3 2020 sales: $159 million

Sponsor(s): Bristol Myers Squibb and Acceleron Pharma

Type: Erythroid maturation agent

Indication(s): Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions; anemia failing an erythropoiesis stimulating agent and requiring two or more RBC units over eight weeks in adult patients

FDA Approval Date: November 8, 2019

4. Ruxience™ *(rituximab-pvvr)*

Q1–Q3 2020 sales: $78 million

Sponsor(s): Pfizer

Type: CD20-directed cytolytic antibody; biosimilar to Rituxan® (rituximab), co-marketed by Genentech and Biogen

Indication(s): Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis

FDA Approval Date: July 23, 2019

5. Trodelvy™ *(sacituzumab govitecan-hziy)*

Q1–Q3 2020 sales: $73.0 million

Sponsor(s): Immunomedics

Type: Trop-2-directed antibody and topoisomerase inhibitor conjugate

Indication(s): Treatment of adults with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease (Trodelvy was granted accelerated approval)

FDA Approval Date: April 22, 2020

6. Adakveo® *(crizanlizumab-tmca)*

Q1–Q3 2020 sales: $71 million

Sponsor(s): Novartis

Type: Selectin blocker

Indication(s): Reduce the frequency of vaso-occlusive crises in adults and pediatric patients aged 16 years and older with sickle-cell disease

FDA Approval Date: November 15, 2019

7. Ubrelvy® *(ubrogepant)*

Q1–Q3 2020 sales: $60 million

Sponsor(s): AbbVie

Type: Calcitonin gene–related peptide receptor antagonist

Indication(s): Acute treatment of migraine with or without aura in adults

FDA Approval Date: December 23, 2019

8. REGEN-COV2 *(casirivimab and imdevimab)*

Q1–Q3 2020 sales: $40.2 million

Sponsor(s): Regeneron Pharmaceuticals

Type: Combination or "cocktail" of two monoclonal antibodies

Indication(s): Treatment of mild to moderate COVID-19 in adults, as well as in pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19

FDA Approval Date: November 21, 2020

9. Zepzelca™ *(lurbinectedin)*

Q1–Q3 2020 sales: $36.9 million

Sponsor(s): Jazz Pharmaceuticals

Type: Alkylating drug designed to bind guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix toward the major groove

Indication(s): Treatment of adults with metastatic small-cell lung cancer with disease progression

FDA Approval Date: June 15, 2020

10. Nurtec™ ODT *(rimegepant)*

Q1–Q3 2020 sales: $28.513 million

Sponsor(s): Biohaven Pharmaceuticals

Type: Calcitonin gene–related peptide receptor antagonist

Indication(s): Acute treatment of migraine with or without aura in adults

FDA Approval Date: February 27, 2020

11. Sarclisa® *(isatuximab-irfc)*

Q1–Q3 2020 sales: €18 million ($22 million)

Sponsor(s): Sanofi

Type: CD38-directed cytolytic antibody

Indication(s): Multiple myeloma in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, in combination with pomalidomide and dexamethasone

FDA Approval Date: March 2, 2020

12. Qinlock® *(ripretinib)*

Q1–Q3 2020 sales: $20.0 million

Sponsor(s): Deciphera Pharmaceuticals

Type: Tyrosine kinase inhibitor targeting KIT proto-oncogene receptor tyrosine kinase and platelet derived growth factor receptor alpha kinase

Indication(s): Treatment of adults with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors

FDA Approval Date: May 15, 2020

13. Tabrecta™ *(capmatinib)*

Q1–Q3 2020 sales: $18 million

Sponsor(s): Novartis

Type: Kinase inhibitor targeting MET, including the mutant variant produced by exon 14 skipping

Indication(s): Treatment of adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test

FDA Approval Date: May 6, 2020

14. Retevmo™ *(selpercatinib)*

Q1–Q3 2020 sales: $17.9 million

Sponsor(s): Eli Lilly and Company

Type: Kinase inhibitor targeting wild-type RET and multiple mutated RET isoforms as well as VEGFR1 and VEGFR3 with IC_{50} values ranging from 0.92 nM to 67.8 nM

Indication(s): Forms of non-small cell lung cancer (adults), medullary thyroid cancer, and other types of thyroid cancers whose tumors have a mutation or fusion in the RET (rearranged during transfection) gene

FDA Approval Date: May 8, 2020

15. Ayvakit™ *(avapritinib)*

Q1–Q3 2020 sales: $15.3 million

Sponsor(s): Blueprint Medicines

Type: Tyrosine kinase inhibitor targeting PDGFRA and PDGFRA D842 mutants as well as multiple KIT exon 11, 11/17, and 17 mutants with IC_{50} values below 25 nM

Indication(s): Unresectable or metastatic gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha exon 18 mutation

FDA Approval Date: January 9, 2020